perhexiline has been researched along with bepridil in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (21.43) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Sen, S; Sinha, N | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| England, PJ; Smith, SJ | 1 |
| Monteforte, PB; Silver, PJ | 1 |
| Martre, H; Singlas, E; Taburet, AM | 1 |
| Cheucle-Beaughard, M; Duchene-Marullaz, P; Michelin, MT | 1 |
| Gray, LS; Haverstick, DM; Heady, TN; Lindenmuth, MA; Macdonald, TL; McCalmont, WF; Patterson, JR | 1 |
1 review(s) available for perhexiline and bepridil
| Article | Year |
|---|---|
[Clinical pharmacology of calcium inhibitors].
Topics: Age Factors; Animals; Bepridil; Biological Availability; Biotransformation; Calcium Channel Blockers; Diltiazem; Dogs; Half-Life; Humans; Intestinal Absorption; Kidney Failure, Chronic; Kinetics; Liver Diseases; Metabolic Clearance Rate; Nifedipine; Perhexiline; Protein Binding; Pyrrolidines; Rats; Tissue Distribution; Verapamil | 1985 |
13 other study(ies) available for perhexiline and bepridil
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The effects of reported Ca2+ sensitisers on the rates of Ca2+ release from cardiac troponin C and the troponin-tropomyosin complex.
Topics: Animals; Bepridil; Calcium; Cattle; Fluorescent Dyes; Heart; Imidazoles; In Vitro Techniques; Kinetics; Myocardium; Perhexiline; Pyridazines; Structure-Activity Relationship; Tropomyosin; Troponin; Troponin C | 1990 |
Differential effects of pharmacological modulators of cardiac myofibrillar ATPase activity in normal and myopathic (BIO 14.6) hamsters.
Topics: Adenosine Triphosphatases; Animals; Anti-Arrhythmia Agents; Bepridil; Calcium; Calcium Channel Blockers; Cricetinae; Disease Models, Animal; Electrophoresis, Polyacrylamide Gel; Heart Failure; Imidazoles; Male; Myocardium; Myofibrils; Perhexiline; Pyrrolidines; Trifluoperazine | 1988 |
Comparative effects of amiodarone, bepridil and perhexiline on coronary venous flow and several cardiovascular parameters.
Topics: Amines; Amiodarone; Animals; Benzofurans; Benzylamines; Bepridil; Coronary Circulation; Denervation; Dogs; Female; Heart; Heart Rate; Hemodynamics; Male; Oxygen Consumption; Perhexiline; Piperidines; Pyrrolidines; Time Factors | 1980 |
Design, synthesis, and biological evaluation of novel T-Type calcium channel antagonists.
Topics: Animals; Antineoplastic Agents; Bepridil; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Division; Drug Design; Evaluation Studies as Topic; Humans; Inhibitory Concentration 50; Jurkat Cells; Perhexiline; Structure-Activity Relationship; Tumor Cells, Cultured | 2004 |